Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Operating expenses:
Research and development	$ 5,751,940	$ 5,088,621
General and administrative	6,167,177	6,191,845
Goodwill impairment	6,929,258
Depreciation	110,371	67,981
Loss from operations	18,958,746	11,348,447
Other expense (income):
Interest (income) expense, net	(151,647)	48,006
Change in fair value of warrant liability		(22,072,322)
Warrant related expenses		10,225,846
Other financing expenses		2,870,226
Loss from operations before income tax benefit	(18,807,099)	(2,420,203)
Income tax benefit	(437,289)	(1,055,685)
Net loss	(18,369,810)	(1,364,518)
Accretion of Series A cumulative preferred dividends	(85,993)	(1,252,394)
Deemed dividend related to the make-whole provision for the conversion of Series A convertible preferred stock into common stock	(8,167,895)
Net loss attributable to common stockholders	$ (26,623,698)	$ (2,616,912)
Per share information:
Net loss per share of common stock, basic (in dollars per share)	$ (8.21)	$ (3.16)
Net loss per share of common stock, diluted (in dollars per share)	$ (8.21)	$ (29.11)
Weighted average shares outstanding, basic (in shares)	3,242,301	827,575
Weighted average shares outstanding, diluted (in shares)	3,242,301	848,090